SOURCE: Dynavax Technologies

Dynavax Technologies

January 11, 2016 16:43 ET

Dynavax to Present at J.P. Morgan 34th Annual Healthcare Conference

BERKELEY, CA--(Marketwired - January 11, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company will present at the J.P. Morgan 34th Annual Healthcare Conference this week in San Francisco, CA. The presentation will be webcast live and will occur on Thursday, January 14, 2016 at 10:30 a.m. PT.

The live or replayed versions of the webcast will be available by visiting the "Investors" section of the Dynavax website or may be reached directly at:

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit

Contact Information

  • Contact:
    Michael Ostrach
    Chief Financial Officer
    Email contact